Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SPY072 · SPY002

Other · developed by Spyre Therapeutics

Phase 2 Most advanced trial
SYRE Developer
1 Registered trials

What is SPY072?

SPY072 is an investigational drug studied in Hidradenitis Suppurativa (HS).

At a glance

Also known as
SPY002
Drug type
Other
Therapy area
Dermatology
Developer
Spyre Therapeutics, Inc. (SYRE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07766005 Phase 2 Hidradenitis Suppurativa (HS) Recruiting SYRE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hidradenitis Suppurativa (HS)

More from Spyre Therapeutics

Follow SYRE, the company behind SPY072

See SYRE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SYRE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.